Key result
Serum ADMA levels were significantly higher in patients with coronary heart disease compared to healthy controls (1.37 vs 0.812 µmol/L) and demonstrated high diagnostic accuracy with an AUC of 0.95.
Why the study?
Serum asymmetric dimethylarginine (ADMA) levels have been investigated as a cardiovascular risk biomarker in various populations, but no such study had been reported in Pakistan.
Does serum ADMA level accurately detect cardiovascular risk in patients with coronary heart disease?
Cross-Sectional (n=100)
No
Does serum ADMA level accurately detect cardiovascular risk in patients with coronary heart disease?
Serum ADMA levels are significantly elevated in patients with coronary heart disease and demonstrate high diagnostic accuracy (AUC 0.95) as a potential biomarker for cardiovascular risk.
Elevated ADMA may support CV risk stratification in Pakistani CHD patients; leaves open its adoption as a routine biomarker pending validation studies.
Objectives: The diagnostic potential of serum asymmetric dimethylarginine (ADMA) levels as a biomarker for cardiovascular risk has been investigated in various populations, but no such study has been reported in Pakistan. This study aimed to assess the diagnostic efficiency of serum ADMA levels in detecting cardiovascular risk in patients with coronary heart disease (CHD). Methodology: A cross-sectional study was conducted at the Chaudhry Pervaiz Elahi Institute of Cardiology (CPEIC), Wazirabad, Pakistan, using a consecutive sampling technique to ensure randomization. One hundred individuals were divided into two groups (CHD patients and healthy controls), and blood samples were collected between January 2022 and November 2022. Serum ADMA levels were measured using an enzyme-linked immunosorbent assay (ELISA), and statistical analysis was performed to determine the area under the receiver operating characteristic (ROC) curve (AUC). Results: The mean age of CHD patients' serum samples was 58.6 ± 7.39 years (p<0.001) compared to 42.26 ± 14.4 years (p<0.001) in healthy controls. The mean ADMA concentration in the serum of CHD patients was determined as 1.37 ± 0.26 µmol/L (p<0.001) compared to 0.812 ± 0.207 µmol/L (p<0.001) in healthy controls. The AUC on the ROC curve was determined as 0.95, indicating high diagnostic accuracy. ADMA's sensitivity, specificity, and overall accuracy were determined as 82%, 88%, and 85%, respectively. Conclusion: In conclusion, serum ADMA levels demonstrate a promising potential as a biomarker for assessing cardiovascular risk. The findings of this study suggest that ADMA measurements could be utilized as a diagnostic tool in CHD patients, aiding in the identification and management of cardiovascular risk in the Pakistani population. Further research is warranted to validate these findings and explore the utility of ADMA in more extensive and diverse cohorts.
No takes yet. Share an insight, caveat, or question.
Roomi et al. (2023) conducted a cross-sectional in Coronary heart disease (n=100). Serum ADMA levels vs. Healthy controls was evaluated on Diagnostic accuracy of serum ADMA levels (Area Under the Curve) (AUC 0.95, p=<0.001). Serum ADMA levels were significantly higher in patients with coronary heart disease compared to healthy controls (1.37 vs 0.812 µmol/L) and demonstrated high diagnostic accuracy with an AUC of 0.95.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: